GW-0742 + SR-9011 Stack – Product Information
GW-0742 and SR-9011 are two distinct research compounds known for their potential beneficial effects in various research settings. When studied together in a stack, they may complement each other, potentially enhancing their individual properties.
- This stack consists of two compounds: GW-0742 and SR-9011.
- GW-0742 + SR-9011 tablets are offered in 2 variants: 10mg GW-0742 and 10mg SR-9011, totaling 20mg per tablet for 27 tablets or 540mg in total, and 20mg per tablet for 54 tablets or 1080mg in total.
- GW-0742 + SR-9011 Capsules consist of 10mg GW-0742 and 10mg SR-9011, totaling 20mg per capsule for 60 capsules and 1200mg in total.
- GW-0742 + SR-9011 Injectable is offered as 35mg SR-9011 and 35mg GW-0742, totaling 70mg per ml for 10ml or 700mg in total.
GW-0742 is a PPARÎ²/Î´ agonist, which is being dubbed as a âSuper Cardarineâ. Studies have shown GW0742 has the ability to improve glucose homeostasis and increase insulin sensitivity in diabetic rats. In diabetic rats fed a high fructose diet, a group given GW0742 showed lower blood sugar compared to the control group. Due to GW0742 being a PPAR agonist, it showed the potential in increasing fat loss by boosting metabolism and stimulating the utilization of fat for fuel. This could potentially increase the oxidative capacity of muscles helping burn more calories.
A recent study on diet-induced obese mice treated with SR-9009 and SR-9011 (i.e., two times a day for 30 days) has been reported to display decreased fat mass and markedly improved dyslipidemia and hyperglycemia. The activation of REV-ERB leads to the enhancement of circadian rhythm observed in mice. This affects behavior, sleep cycle, and some functions related to an increment in energy production.